Drug Profile
Research programme: small molecule therapeutics - Advanced Pharmaceuticals
Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Advanced Pharmaceuticals
- Class Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Globoid cell leukodystrophy; Multiple sclerosis; Parkinson's disease
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Globoid-cell-leukodystrophy in USA
- 28 May 2022 No recent reports of development identified for research development in Multiple-sclerosis in USA
- 28 May 2022 No recent reports of development identified for research development in Parkinson's-disease in USA